Intervention

Lopinavir/ritonavir

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 31 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials31

Recruiting0

Common conditions14

Lead sponsors shown15

Clinical trials

31 shown

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19NCT04394182 · 2020-04-21

Antiretroviral Regime for Viral Eradication in NewbornsNCT02712801 · 2016-04-01

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-InfectedNCT01632891 · 2014-01-10

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing GuidelinesNCT01172535 · 2010-11-01

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant WomenNCT00993031 · 2009-12-15

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.NCT00945282 · 2009-10-20

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-RegimensNCT00994344 · 2009-10-01

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected AdultsNCT00608569 · 2009-03-01

Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)NCT00665951 · 2008-09-01

Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/rNCT00866021 · 2008-02-01

Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During PregnancyNCT00605098 · 2008-02-01

Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV PatientsNCT00661349 · 2008-02-01

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving BirthNCT00109590 · 2006-06-01

Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIVNCT00307151 · 2005-12-01

Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and WomenNCT00102986 · 2005-10-01

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 InfectionNCT00105079 · 2005-04-01

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVNCT00307502 · 2005-01-01

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIVNCT00086359 · 2004-07-01

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk FactorsNCT00720590 · 2003-11-01

When to Start Anti-HIV Drugs in Patients With Opportunistic InfectionsNCT00055120 · 2003-03-01

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended AccessNCT01003990 · 2002-10-01

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected SubjectsNCT00043953 · 2002-08-01

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve SubjectsNCT00043966 · 2002-07-01

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase InhibitorsNCT00038636 · 2000-09-01

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected PatientsNCT00038220 · 2000-07-01

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected AdultsNCT00100581

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIVNCT00084058

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive PatientsNCT00050895

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior TherapyNCT00102206

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected WomenNCT00125983

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceNCT00046033

Common conditions

HIV Infections24 HIV2 Pregnancy2 AIDS-Related Opportunistic Infections1 Cytokine Storm1 Endothelial Dysfunction1 Hepatitis C1 HIV-1 Infection1 HIV/AIDS and Infections1 HIV/HCV Co-infection1 Infection, Human Immunodeficiency Virus1 Malaria1 Pf Subclinical Parasitemia1 Pneumonia, Viral1

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 11 Abbott 4 Germans Trias i Pujol Hospital 3 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 2 Bristol-Myers Squibb 1 Fundacion GenesisCare 1 Fundacion SEIMC-GESIDA 1 Hoffmann-La Roche 1 Indiana University 1 International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1 National Center for Women and Children's Health, China CDC 1 Oswaldo Cruz Foundation 1 Radboud University Medical Center 1 University of California, San Francisco 1 ViiV Healthcare 1

Trial status mix

COMPLETED29

SUSPENDED1

TERMINATED1

Phase mix

PHASE211

PHASE38

PHASE46

NA5

PHASE14

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.